

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>3</sup>: C07C 103/52; C07D 237/32; C12Q 1/38</p>	<p>A1</p>	<p>(11) International Publication Number: WO 82/00641 (43) International Publication Date: 4 March 1982 (04.03.82)</p>
<p>(21) International Application Number: PCT/SE81/00235 (22) International Filing Date: 24 August 1981 (24.08.81) (31) Priority Application Number: 8005940-5 (32) Priority Date: 25 August 1980 (25.08.80) (33) Priority Country: SE  (71) Applicant: KABIVITRUM AB [SE/SE]; S-112 87 Stockholm (SE). (72) Inventors: SIMONSSON, Leif, Roger; Olshammsgatan 10, S-422 47 Hisings Backa (SE). ARIELLY, Salo; Violgatan 3A, S-434 00 Kungsbacka (SE). AURELL, Leif, Erik; Gamla Kyrkstigen 13, Box 4152, S-430 40 Särö (SE). CLAESON, Karl, Göran; Strandstigen 13, S-181 34 Lidingö (SE). (74) Agents: WURM, Bengt, R. et al.; AB Astra, Patent and Trade Mark Department, S-151 85 Södertälje (SE).</p>		<p>(81) Designated States: JP, SU.  Published <i>With international search report</i></p>
<p>(54) Title: PEPTIDE SUBSTRATES FOR DETERMINATION OF PROTEASE ACTIVITY</p> <p>(57) Abstract</p> <p>Novel peptide derivatives which are acyl derivatives of luminol (5-amino-2,3-dihydro-1,4-phthalazinedione) or isoluminol (6-amino-2,3-dihydro-1,4-phthalazinedione) where the acyl residue is an amino acid or amino acid sequence with 2 to 4 amino acid residues, coupled with an amide bond, and where the <math>\alpha</math>-amino group is either free or acylated, methods for their preparation and a method for laboratory diagnostics of proteases using the peptide derivatives. The derivatives are intended for quantitative determination of proteases or protease-activity by release of luminol or isoluminol which in their free state can be brought to luminate intensely, but lose considerably in luminescence when they are amidebound to a peptide sequence.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AT</b>	Austria	<b>KP</b>	Democratic People's Republic of Korea
<b>AU</b>	Australia	<b>LI</b>	Liechtenstein
<b>BR</b>	Brazil	<b>LU</b>	Luxembourg
<b>CF</b>	Central African Republic	<b>MC</b>	Monaco
<b>CG</b>	Congo	<b>MG</b>	Madagascar
<b>CH</b>	Switzerland	<b>MW</b>	Malawi
<b>CM</b>	Cameroon	<b>NL</b>	Netherlands
<b>DE</b>	Germany, Federal Republic of	<b>NO</b>	Norway
<b>DK</b>	Denmark	<b>RO</b>	Romania
<b>FI</b>	Finland	<b>SE</b>	Sweden
<b>FR</b>	France	<b>SN</b>	Senegal
<b>GA</b>	Gabon	<b>SU</b>	Soviet Union
<b>GB</b>	United Kingdom	<b>TD</b>	Chad
<b>HU</b>	Hungary	<b>TG</b>	Togo
<b>JP</b>	Japan	<b>US</b>	United States of America

Peptide Substrates for Determination of Protease ActivityTechnical area

- Protein-splitting enzymes, so-called proteases, have a number of vital functions in the human body. Trypsin and chymotrypsin are secreted from the pancreas and are active in the digestion process; elastases, kallikreins and chathepsins of various kinds, as well as the enzymes of the complement system, participate, among others, in reactions caused by inflammatory and allergic conditions; thrombin and factors IXa, Xa, XIa and XIIa are proteases in the chain of reactions leading to the formation of blood clots; endogeneous plasmin and exogeneous urokinase are proteases causing lysis of blood clots, etc.
- An assay of the level of such proteases is of great importance in many situations. Its makes possible the indirect assay of proenzyme levels by specific activation of such proenzyme, as well as the direct determination of the amount of active enzymes and also the level of their activators and inhibitors (as, for instance, plasminogen activators via plasmin, factor VIII via FX, heparin and anti-thrombin via Factor X of thrombin,  $\alpha_2$ -antiplasmin via plasmin streptokinase via plasminogen, etc.).
- Such assays are required, of course, in examinations of pathological conditions, but the determination of certain of these parameters is also of great importance in the preparations for surgical and medicinal treatment. Furthermore, the assay of protease activity is highly important and of great interest to biochemical reasearch in view of the many physiological functions performed by proteases. Neither are the proteases concerned limited to only higher mammals. Proteases isolated from microorganisms are used in chemo-technical and food industry. One highly important method for the assay of endotoxin is based on the ability



of endotoxin to activate a protein isolated from certain exotic crabs. The protease activity generated is proportional to the quantity of endotoxin (the so-called Limulus test).

5

### Background

The established procedure for quantitative assay of proteases is based either on immunological techniques or  
10 reaction with some kind of substrate biological or synthetic.

Immunological methods utilizing the antibody-antigen reaction can, of course, be used with all proteases with  
15 available specific antibodies. There are, however, two important drawbacks - the method is time-consuming because the result does not appear till after 1 - 24 hours, and it is not sufficiently discriminative in so far as the protein - functionally active or not - reacts with its antibody as  
20 long as the antigenic structure (the determinant) is intact. Thus, the immunologically assayable quantity of a protein is equal to or larger than the quantity of functionally active protein. The advantage of the method, however, is its specificity and high sensitivity.

25

Examples of reactions with natural substrates used for protein determination are: the reaction of thrombin with fibrinogen in coagulation, the plasmin reaction with fibrin in fibrinolysis, and the elastase reaction with elastine.  
30 Thus, the usual diagnostic methods used in the field of coagulation are mostly based on the fact that plasma samples are activated under standardized conditions and the final reaction step is the reaction of thrombin with fibrinogen. In this procedure, fibrinogen is transferred to  
35 insoluble fibrin, the forming of which is the final step of the assay. Another example is the horseshoe crab haemocyte-

lysate which coagulates after endotoxin activation of its clotting enzyme (Limulus test of endotoxin).

Other methods for the determination of proteases use  
5 biological proteins which are not in themselves natural substrates for the protease in question. Examples: casein, haemoglobin, gelatine and insulin.

The disadvantage of working with protein substrates is the  
10 usually very limited sensitivity and lack of specificity of these methods. Further, they are difficult to standardize, are rather time-consuming and cannot easily be automatized.

15 Synthetic, low-molecular weight substrates based on amino acids or short peptides provided with a marker easily determinable and easily split by proteases have, in recent years, considerably facilitated the methods for quantification of proteases by eliminating several of the above-  
20 mentioned disadvantages.

These substrates - being organic synthetic chemicals - have in common the quality of being easily standardized. Further, there is the possibility of making these substrates more or  
25 less specific for various types of proteases by a tactical choice of the amino acid or amino acid sequence linked to the marker. Thus, the choice of the suitable substrate structure can be adapted to the actual demand. In addition, this kind of substrates permit the use of markers to be  
30 liberated in the protease reaction and, thus, easily quantified in an objective measuring equipment (spectrophotometer, fluorimeter, radioactivity counter).

Two types of derivatives have been utilized as substrates,  
35 esters or amide derivatives of the markers. As a rule, the ester substrates have proved to be more easily split than

BAD ORIGINAL



the corresponding amide derivatives. At the same time, however, splitting of amide derivatives is a physiologically and biochemically better model of the specific function of proteases which is splitting of amide bindings.

- 5 In addition, the ability of a protease to split esters and amides is in certain cases related to different reaction centers within the molecule which means that, in such a case, amide substrates are required in order to be able to determine the physiological function.

10

Among the markers used in synthetic substrates of the amide type according to the foregoing, derivatives of p-nitroaniline (pNA) for photometric quantification and of  $\beta$ -naphthylamin ( $\beta$ NA) as well as of 2-amino-4-methylcoumarin  
15 (MCA) for fluorometric quantification are the most commonly used and described, according to information available from the literature and accessible patent documents.

Substrates with radioactive labelled markers are sporadically  
20 cally mentioned in the literature but, as the properties of an intact substrate and a split-off marker do not differ in regard to radioactivity, a separation step is required before the assay. This complication, in addition to the risk involved in the handling of radioactive material and  
25 the problem of lack of stability of the substrate due to the natural decompositions of the radioactive isotope introduced in the substrate, has made this kind of substrate useful only in very special instances.

30 Comprehensive studies have been carried out with synthetic substrates - usually provided with pNA or MCA markers - in order to establish structures which, with a limited number of amino acids in the peptide part (usually 2 to 4), provide an optimum of sensitivity and specificity for a  
35 number of endo- and exogenic proteases important from the clinical point of view. It has been found that the pNA- or

MCA marker, respectively, is of no decisive significance to the general properties of the substrates. Thus, the specificity profile of a substrate, that is, its relative reactivity to various enzymes, is mainly governed by the peptide structure. Further, the differences in  $K_m$  and  $k_{cat}$  values do not give differences in substrate turnover rate in terms of "moles substrate converted per time unit" larger than usually about 10 times. If, furthermore, the solubility of each substrate allows for substrate concentration stronger than twice the  $K_m$ -concentration, only  $k_{cat}$  is essential. The differences mentioned in the literature may, in certain cases, also be explained by different buffer systems and contents of organic solvents.

Thus, the capacity of each substrate for assaying low levels or small amounts of a certain enzyme is primarily determined by the possibility to determine low levels or small volumes of each marker after its release from the substrate.

20

The smallest content of MCA in pure aqueous solutions which can be determined photometrically or fluorimetrically would be  $10^{-6}$  M or  $10^{-9}$  M respectively. But as also intact substrate in considerably higher concentration is present in the solution in protease assays with chromogenic and fluorogenic synthetic substrates, the sensitivity of the methods is limited by the background effect supplied by unsplit substrate - in particular when minute concentrations of released marker are to be determined.

30


This difference is due to the fact that the properties of the marker are not the same when it is free and when it is acylated by an amino acid or a peptide. Whichever amino acid or peptide forms the acyl group is of minor importance. Thus, the difference between an MCA substrate and free MCA is 500 to 700, that is, the fluorimeter reading is the same

for  $1,5 - 2 \cdot 10^{-7}$  M MCA as for a  $1 \cdot 10^{-4}$  M MCA substrate solution (Zimmermann et al., Anal Biochem 70, 258 (1976), ibid. 78, 47 (1977), Proc Natl Acad Sci USA 75, 750 (1978). The linear response is said to be obtained for a 500-fold concentration range.

The smallest determinable volume depends on the type of appliance used but usually a volume of 0.5 to 3 ml is required for the photo- and fluorometric methods - volumes of less than 0.5 ml require special equipment for exact determination because both types of marker require a certain amount of radiation to give an exact measure of the light quantity absorbed or emitted.

#### 15 Description of the invention

The present invention relates to a new typ of marker for the determination of protease activity. It is based on the fact known per se that compounds of the cyclic diacylhydrazide type



$R_1=H, R_2=NH_2 \Rightarrow$  luminol (5-amino-2,3-dihydrophthalazin-1,4-dion)

$R_1=NH_2, R_2=H \Rightarrow$  isoluminol (6-amino-2,3-dihydrophthalazin-1,4-dion)

can be brought to emit light by addition of an oxidizer.

30 This is the phenomenon known as chemiluminescence (CL). The special case when the reaction is being catalyzed by an enzyme is referred to as bioluminescence (BL). Analytical techniques such as photometry and fluorometry are based on the changes caused by the samples on the incoming light.

35 CL uses chemical reactions causing excited conditions in one or more of the reactants, recess to the ground state



being followed by emission of light. In other words, chemiluminescence is an emission process while photometry and fluorometry are based on the absorption process. A summary on the subject relating to its application in analytical biochemistry is given in Methods in Enzymology, Vol. 57, ed. deLuca, Acad Press, New York 1978, and relating to its use in clinical chemistry in Whitehead et al., Clin Chem 25, 1531 (1979), and Gorus & Schram, ibid. 25, 512 (1979).

10

A number of analytical applications utilizing luminiscent reactions have been documented. They are based on the principle that either one of the reactants in the oxidation reaction appears in a concentration so small that its level determines the speed and thus becomes determinable (e.g. ATP, NADH (BL) and  $H_2O_2$  (CL)), or that the substance to be determined consumes or produces or in some other way is linked to the reactants of the oxidation system to the effect that its concentration indirectly limits the reaction process (e.g. ADK, kreatine phosphate via ATP, malate, and FMN via NADH, as well as glucose and haemoglobin via  $H_2O_2$ ). Further, BL and CL have been used for immunoassays, both direct by binding for instance, luminol or isoluminol to an antibody or antigen as a marker, or by using a BL catalysing enzyme or other co-factor in the same way.

The present invention is based partly on the observations described in the experimental part, namely that acylated and non-acylated derivatives of isoluminol and luminol have quite different properties as regards the capacity of emitting light under standard conditions for the oxidation reaction, partly on the fact that - if the acyl group consists of an amino acid or a peptide, or a derivative of either - proteolytic enzymes can split such compounds to the effect that isoluminol or luminol is released and can be measured by addition of excess of the

other reactants of the oxidation reaction. Thus, utilizing the fact known per se that amino acid derivatives and peptide derivatives containing 2 to 4 tactically chosen amino acid residues have high affinity to a number of  
5 important and well characterized proteases, the present invention shows a new type of substrates for the determination of the abovementioned type of proteases. These substrates allow the quantification of very low concentrations and small volumes in equipment technically less  
10 complicated than spectrophotometers and fluorimeters.

Due to the fact that such parameters as

15 type of buffer system,  
reaction time,  
reaction temperature,  
substrate concentration,  
enzyme purity, etc.

20 all influence the definition of the lowest protease activity (unit or quantity per test volume) assayable with a certain method, the sensitivity limit of the different methods is here defined by the quantity of free marker  
assayable in the presence of a certain concentration of  
25 intact substrate. All such concentration values refer to the substrate-enzyme solution.

Depending on the dilution factor and type of oxidation step, isoluminol and luminol in "pure" systems are  
30 assayable down to the concentration  $3 \cdot 10^{-10}$  and  $10^{-11} - 10^{-10}$  M respectively. Due to the fact that the substrates according to the present invention show unexpected great difference in their light emission capacity as compared with corresponding concentrations  
35 of free marker (usually 2,500 - 10,000) isoluminol, for instance, is assayable in concentrations as low as

1 · 10<sup>-9</sup> M. There is linearity up to 10<sup>-5</sup> M and, thus, the assay area covers a 10<sup>4</sup> - fold concentration range. The analyses only require 10 to 15 µl volume of a substrate-enzyme solution.

5

The advantages of the compounds according to the invention are

- 10 - the fact that, as distinguished from the MCA-marked fluorogenic substrates which to-day are considered as being highly sensitive, the compounds according to the invention permit the determination of a change in concentration of 1 · 10<sup>-9</sup> M of free marker in the presence of 1 · 10<sup>-4</sup> M substrate, compared with  
15 1 · 10<sup>-7</sup> MCA and 1 · 10<sup>-6</sup> pNA which fact know per se means considerably increased sensitivity in the assay of extremely low protease concentration with synthetic substrates;
- 20 - the fact that these compounds permit assays within a much wider concentration range: 1,000 to 10,000 times for isoluminol, 500 to 700 times for MCA and 100 times for pNA of free marker in the same appliance merely by choosing a suitable area of sensitivity;
- 25 - the fact that these compounds - as distinguished from very easily split ester substrates - are amides and thus reflect the catalytic function of the enzyme more truly than is the case with an ester substrate. At the same  
30 time, they are chemically more stable in neutral or slightly basic environments than are ester substrates of the type p-nitrophenylester or umbelliferone;
- 35 - the fact that these compounds as distinguished from radioactive labelled substrates which to-day are considered as being highly sensitive have the advantage

BAD ORIGINAL



SUBSTITUTE SHEET

not only of the absence of radioactivity and spontaneous decomposition but also permit assays of the reaction solution without previous separation step for the isolation of the reaction products;

5

- the fact that these compounds as distinguished from chromophore and fluorophore-marked substrates which are in common use to-day permit determinations of minute quantities of substrate-enzyme solution - of the size  
10 10 to 50  $\mu$ l - in standard appliances for luminescence assays which latter also are technically less complicated and thus less expensive than spectrophotometer and fluorometer - all taken together resulting in lower costs for analyses with regard both to reagent and  
15 appliance;

- the fact that, as distinguished from, for instance, fluorogenic compounds, the compounds according to the invention generate markers less sensitive to deacti-  
20 vating interference such as chemical quenching which, among other things, is achieved by a dilution step preceding the oxidation step.

## 25 Experimental part

### I. General specification

When using substrates according to the invention, the  
30 commonly used buffer systems for enzyme-substrate reactions can be applied as, for instance, tris, tris-imidazole, phosphate, barbiturate, veronal or glycine buffer, with suitable addition of base or acid and inorganic salts for obtaining best possible conditions with regard to pH and  
35 ionic strength for the reaction of enzyme with substrate.

Following the selected reaction time which usually is 0.5 to 10 minutes, the reaction is discontinued either in all of the enzyme-substrate solution or in part of the same by adding base or acid to obtain a change in pH effective enough to stop the enzymatic hydrolysis of the substrate.

Then the quantity of released CL-marker (luminol or isoluminol) is determined by adding suitable oxidizer and measuring the thus emitted amount of light in a suitable appliance. Due to the fact that the amount of released marker is in linear proportion to the amount of enzyme, and the light quantity emitted is in linear proportion to the amount of CL-marker, the light quantity constitutes the measure of protease quantity (protease activity).

Adequate oxidation system are, for instance,

- aqueous solution of hydrogenperoxide ( $H_2O_2$ ) in the presence of a catalyst of oxidation promoting compound, such as
  - o various kinds of peroxidases, catalases and other biological compounds which are derivatives of the haemo group, for instance, microperoxidase,
  - o hematin,
  - o several metal ions, for instance,  $Cu^{2+}$ ,  $Co^{2+}$ ,  $Cr^{3+}$ ,  $Fe^{2+}$ ,
  - o ferric cyanide ( $(K_3Fe(CN)_6)$ ).
- hypochlorite, persulphate, permanganate, periodate, perborate,
- oxygen in the presence of suitable catalysts,

- superoxides ( $\text{KO}_2$ ) if the reaction determination is made in an anhydric system.

- Hydrogenperoxide plus hematin as well as hydrogenperoxide plus microperoxidase or catalase have proved to be particularly well suited as oxidation systems for the determination of CL-marker from substrates of the present invention.
- 10 The light emission is pH dependent. Thus, the reactions with hematin should be performed at a pH of 10 to 13, and reactions with microperoxidase at pH 8 to 13 to obtain the best possible results.
- 15 The substrate-enzyme reaction solution only being a limited portion of the CL determination reaction solution each reaction can be performed at its most favourable pH value.
- 20 Substrates according to the present invention can be used with commercially available luminescence meters (for instance, LKB Luminometer 1250, Aminco Chem-Glow Photometer) and also in equipment specially made for the purpose, as long as this equipment comprises a light detector
- 25 (photomultiplier tube or photosensitive diode), amplifier and signal converter, signal recorder unit (analogue or digital "display", printer or recorder) as well as a completely dark reaction chamber with facilities for direct test injection.
- 30
- The speed of CL reactions varies. In the case of oxidation of isoluminol or luminol with  $\text{H}_2\text{O}_2$  and catalyst or an oxidation promoting compound, light emission is a very rapid and rather short-lived reaction which, in practice,
- 35 starts at the moment when the last reagent is placed in the reaction vessel, that is, less than 2 seconds after


that addition. The quantity of light is obtained either by integration of the light intensity over a certain time interval or - when the process proceeds as fast as mentioned in the example above - simply by measuring the peak height of the recorded signal.

By comparison of the quantity of light emitted with that obtained from samples of marker with known concentrations - possibly making adjustments on account of additional light intensity due to background emission from, for instance, intact substrate and the components of the oxidation system - the molar quantity of marker released per time and enzyme unit can be determined, as well as kinetic parameters. The enzyme concentration of an unknown sample is best determined by comparison with a standard graph obtained by using known enzyme concentrations under equal conditions.

In the synthesis of substrates according to the invention, traditional methods well-known in peptide chemistry are adapted. The synthesizing procedure is, however, facilitated if the luminol and isoluminol in the acylation reactions are introduced as 3- and 4-amino-N-methylphthalimide (ANMP), respectively, in particular when the first (C-terminal) amino acid is to be coupled. By conversion of the acyl derivative thus obtained of 3- or 4-ANMP with hydrazine hydrate in ethanol or dimethylformamide, it is transferred to the corresponding luminol and isoluminol derivatives respectively.

30

35



It appears then that ANMP-derivatives are stable against the commonly used deprotection and coupling reactions and that hydrazinolysis can take place without detriment to any components of the amino acid or peptide structure.

- 5 This is illustrated by the experiments described in the following.

For condensation of ANMP and a properly protected amino acid, adequate coupling methods are the ones commonly  
10 used for the corresponding condensation of anilin and anilin derivatives with amino acids and peptides as, for instance, the so-called phosphaza method, mixed anhydride method, or the use of a coupling agent such as EEDQ (N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline), or  
15 DCCI, possibly in the presence of an activating alcohol such as N-hydroxysuccinimide or N-hydroxybenzotriazole.

The principle of synthesizing peptide derivatives according to the invention may be a step-wise addition of amino  
20 acids to the C-terminal amino acid residue, either initially linked to the CL-marker on ANMP or furnished with a removable carboxyl protection group in which case ANMP is subsequently coupled to the protected peptide derivative. Alternatively, the N-terminal peptide may be  
25 synthesized separately and then linked to the C-terminal amino acid residue having a CL-marker, ANMP or a removable carboxyl protecting group coupled to it as described in the foregoing.

30 Whichever principle is chosen, purifications of the intermediate and products by gel filtration chromatography is most suitable because this method warrants rapid synthesis and maximal yields.

35 As an amino protecting group, the carbobenzoxy- or t-butyloxycarbonyl group or related groups, such as the



p-methoxy, p-nitro or p-methoxyphenylazocarbobenzoxy group, are recommended.

For protection of the guanidino group of the arginine,  
5 the use of protonisation, the nitro group or the p-toluenesulphonyl group have proved to be adequate.

The hydroxyl group of tyrosine, serine and threonine is adequately protected by the t-butyl or benzyl group.  
10 Methyl-, ethyl- or benzylester is an adequate removable carboxyl protecting group.

The coupling of two amino acids or a peptide fragment and an amino acid is obtained by activating the  $\alpha$ -carboxyl  
15 group. The activated derivative may either be isolated or generated in situ and may be, for instance, p-nitrophenyl, trichlorophenyl, pentachlorophenyl, pentafluorophenyl, N-hydroxybenzotriazole or N-hydroxysuccinimido ester, symmetric or assymetric anhydride or azide. The usual  
20 coupling agents for direct coupling or generating the mentioned esters are dicyclohexylcarbodiimide, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline or their equivalents.

The protecting groups are completely or partly removed by  
25 a tactical choice of protecting groups and deprotecting methods. For example: The carbobenzoxy group is split off with hydrogen bromide in acetic acid, and the t-butyloxy group with trifluoro acetic acid. Esters are hydrolysed with sodium hydroxide solution. For complete deprotecting,  
30 hydrofluoric acid and, sometimes, hydrogen gas in the presence of a catalyst, are suitable reagents.

A suitable method for purifying intermediate or end products is not only crystallization, but also gel  
35 filtration chromatography on cross-linked dextran gels of the type Sephadex<sup>®</sup> as a solid phase. Sephadex<sup>®</sup> is to be

used with either aqueous solutions (G-15 or G-25) with an addition of 5 to 30% acetic acid, or with alcohol solutions - preferably methanol - (LH-20), or for ion exchange chromatography in mixtures of alcohol and water (QAE-A-25).

5

Reaction solutions, intermediate products, eluates from column chromatography as well as end products obtained in solid form by lyophilization from water or water and acetic acid, or alcohol, are checked by thin-layer chromatography. Here, pre-fabricated glass plates, with silica gel F<sub>254</sub> (Merck) as an absorption medium, are used.

10

The solvent systems used are

15	P <sub>1</sub>	CHCl <sub>3</sub> , MeOH	9:1	(volume)
	P <sub>a</sub>	CHCl <sub>3</sub> , MeOH, AcOH	17:2:2	
	P <sub>a6</sub>	CHCl <sub>3</sub> , MeOH, AcOH, H <sub>2</sub> O	34:4:9:2	
	A	n-BuOH, AcOH, H <sub>2</sub> O	3:1:1	
	M	n-BuOH, AcOH, pyridine, H <sub>2</sub> O	15:3:10:12	
20	M <sub>3</sub>	EtOAc, AcOH, pyridine, H <sub>2</sub> O	30:60:20:11	

Following chromatography, the plate is inspected in UV light (254 nm) and then developed with ninhydrine and with a chlorine/dicarboxidine reagent according to normal procedure. All end products are homogeneous according to TLC performed on a quantity of 50 - 100 µg. The given R<sub>f</sub> values are the results of single runs.

25

An amino acid analysis of the end product shows that in all cases these products contain the expected amino acids, and the relative contents of the respective amino acid residue lie within ± 5% of the expected values.

30

The optical activity of the end product is determined at 589 nm in 50% acetic acid at a concentration of 0.2 to 1.0 g/100 ml (c = 0.2 to 1.0).

35

The homogeneity of the end product is also checked by high performance liquid chromatography using C<sub>18</sub>-derived silica gel as a solid phase and 40% methanol in 0.1 M sodium acetate, pH 4,6, as an eluant, and UV light at 254 nm as a detection method. This method also provides a check that no free marker pollutes the end product.

The following experimental data show that luminol and isoluminol are generally applicable as markers of protease substrates.

## II. Synthesis

Peptide synthesis distinguished itself by the fact that a number of standard reactions may be used independently of amino acid structure and peptide size and, therefore, these standard reactions are described in the following while the synthesized compounds are listed in the table with reference made to the described reactions.

### Abbreviations:

(Unless otherwise stated, all amino acids have the L-configuration.)

Arg = Arginine	Leu = Leucine
Phe = Phenyl alanine	Tyr = Tyrosine
Pip = Pípecolinic acid	pGlu = Pyroglutamic acid
Pro = Proline	Glu = Glutamic acid
Val = Valine	Ser = Serine
Ala = Alanine	Gly = Glycine
Ile = Isoleucine	Lys = Lysine

	AcOH	= Acetic acid	HOBt	= N-Hydroxybenzotriazole
	TFA	= Trifluoro acetic acid	DCCI	= Dicyclohexyl-carbodiimide
	Boc-	= t-Butyloxycarbonyl	Lum	= Luminol
5	CbO-	= Carbobenzoxy	Isl	= Isoluminol
	DMF	= Dimethyl formamide	Bzl-	= Benzyl
	Et <sub>3</sub> N	= Triethylamine	Bz-	= Benzoyl
	EtOAc	= Ethyl acetate	Git	= Glutaryl
	EtOH	= Ethanol	Tos-	= p-Toluenensulphonyl
10	MeOH	= Methanol	Ac-	= Acetyl
	n-BuOH	= n-Butanol	Suc-	= Succinyl
	ANMP	= Amino-N-methyl-phthalimide		
15	HOSu	= N-hydroxy-succinimide		
	TLC	= Thin Layer Chromatography		
	GPC	= Gel Permeation Chromatography		
	HPLC	= High Performance Liquid Chromatography		
20	I	= Ionic strength		

# Reaction\_type\_A

## 25 Coupling of 3- or 4-ANMP

30 mmol of 3- or 4-ANMP (5.28 g) is suspended in 100 ml of anhydrous pyridine, and 1.4 ml PCl<sub>3</sub> dissolved in 20 ml of pyridine is added dropwise at 0°C while the mixture is being stirred. After 30-45 minutes at room temperature, 30 mmol of aminoprotected amino acid or peptide is added. When the solution has cleared (usually after 24 to 72 hours), the completeness of the reaction is checked by TLC. Evaporation and processing by acid and basic washings produce an oily residue which can be crystallized from EtOH or MeOH, possibly after an addition of water. Yield: 70 to 85%.

Reaction\_type\_BRemoval of Cbo-, Boc and Bzl-O- groups

- 5 10 mmol of the thoroughly dried Cbo-derivative is suspended in 25 ml of dry AcOH, and 15 ml 5.6 N HBr is added under moisture free conditions at room temperature.

After reacting for 45-60 minutes, the solution is poured  
10 into 300 ml of dry ether while it is being stirred vigorously. The ether solution is sucked off the resulting precipitate which is then washed with 2 to 3 portions of 100 ml ether each. The thus obtained hydrobromide of N<sup>α</sup>-deblocked compound is dried over NaOH pellets in vacuo at  
15 40°C for 3 to 16 hours.

Reaction\_type\_C20 Removal of Boc group

- 10 mmol of the thoroughly dried Boc derivative is dissolved in 200 ml of 25% TFA in CH<sub>2</sub>Cl<sub>2</sub> under moisturefree conditions at room temperature. After reacting for 20 minutes,  
25 the solution is poured into 500 ml of dry ether. After filtering, the resulting precipitate is washed with large quantities of ether. The thus obtained trifluoro acetate of N<sup>α</sup>-deblocked compound is dried over NaOH pellets in vacuo at 30°C for 2 to 3 hours.

30

Reaction types D, E and FCoupling reactions5 Releasing  $\alpha$ -amino group

For acylation of the derivatives obtained according to reaction type B or C, the  $\alpha$ -amino group must be present as a free base. This may be effected in various ways. For instance, an equivalent amount of tertiary amine (for instance,  $\text{Et}_3\text{N}$  or N-ethyl morpholine) may be added to a DMF solution of the HBr or TFA derivative cooled to  $-10^\circ\text{C}$ . In the case of  $\text{Et}_3\text{N} \cdot \text{HBr}$  derivatives, the precipitated  $\text{Et}_3\text{N} \cdot \text{HBr}$  is filtered off. Alternatively, the HBr or TFA derivative may be dissolved in 5% aqueous sodium bicarbonate from which the liberated derivative is extracted into, for instance, EtOAc or butanol; the organic phase is then dried and evaporated.

20 D with an  $\text{N}^\alpha$ -protected, active ester derivative.

11 mol of  $\text{N}^\alpha$ -protected p-nitrophenyl or N-hydroxy-succinimide ester derivative of the amino acid or peptide to be coupled is added, at  $-10^\circ\text{C}$ , to a solution of 10 mmol of peptide or amino acid derivative, obtained according to the foregoing, in 20 to 50 ml of freshly distilled DMF. After reacting for 1 hour at  $-10^\circ\text{C}$ , the solution is buffered with 5 mmol of tertiary amine and allowed slowly to attain room temperature. The reaction process can be followed by TLC analyses. If required, another 5 mmol of base is added after repeated cooling. When the reaction is finished the solution is evaporated to produce an oily residue which is stirred with some portions of water. The rest is purified by GPC or recrystallization. If GPC is used for purification of the coupling product and the latter has an elution volume fully or partly equivalent

to that of the active ester derivative, contamination of the coupling product may be prevented by conversion - after finished reaction but before evaporation - of unconsumed active ester derivative with an excess of 3 to 5 mmol of primary amine, for instance, n-butylamine, for 30 minutes at room temperature. This is followed by processing as in the foregoing.

E with N-protected amino acid or peptide and generating active ester in situ.

At  $-10^{\circ}\text{C}$ , 11 mmol of  $\text{N}^{\alpha}$ -protected amino acid, or equivalently protected peptide derivative with a C-terminally free carboxyl group, 11 mmol HOBT or HOSu and 11 mmol of DCCI are added to a solution of 10 mmol of peptide or amino acid derivative, obtained according to the foregoing, in 20 to 50 ml freshly distilled DMF. After 1 to 30 hours at  $-10^{\circ}\text{C}$ , the reaction solution is allowed to attain room temperature. The reaction process can be followed by TLC analysis. After reaction, the solution is poured into 100 to 300 ml of 5%  $\text{NaHCO}_3$  (aq.) while being stirred, or evaporated to an oily residue which is stirred with some portions of sodium bicarbonate.

The resulting precipitate is washed in water after filtration or pouring off the solvent. It is then purified by GPC or recrystallization.

F with anhydride (F1) or acid chloride (F2)

N-terminal acyl groups are introduced by reacting the amino acid or peptide derivatives obtained according to the foregoing with the anhydride of the corresponding acyl group (for instance, succinyl, glutaryl, benzoyl or acetyl) or the acid chloride of the acyl group (for instance, benzoyl, acetyl or tosyl). Procedure as described in D and E above with regard both to solvent and amounts and to reaction temperatures and processing.

Reaction\_type\_G

Catalytic hydrogenation for removal of Cbo, Benzyl-O and NO<sub>2</sub> groups.

5

5 mmol of peptide is dissolved or suspended in 15 to 50 ml of solvent which may be MeOH, AcOH or mixtures of these, possibly with an addition of 1.2 equivalents of HCl. Then the catalyst, 10% palladium on carbon (Pd/C), is added.

10 Hydrogen gas is introduced and the reaction allowed to continue at room temperature while being stirred until no more hydrogen gas is consumed. (2 to 24 hours.) The catalyst is filtered off, the purity checked by TLC and the desired product isolated either directly by evapora-  
15 tion and perhaps lyophilization, or after GPC. If the derivative is to be used for further acylation reactions with DCCI, compounds existing as acid addition salts of AcOH must be converted to the corresponding HCl salt by GPC ion exchange.

20

Reaction\_type\_H

Removal of all remaining protecting groups

25

0.2 to 1.0 mmol of the fully or partly protected amino acid or peptide derivative is deprotected by being reacted for 60 minutes at 0°C with 5 to 20 ml of dry HF in the presence of 0.2 to 1.0 ml of anisole in equipment built  
30 for this purpose according to Sakakibara.

After reaction and complete distillation of all HF, the crude product is dissolved in 10-30% AcOH in water and possibly shaken with a small amount of ether and purified  
35 by GPC. The product is isolated by lyophilization from diluted AcOH. It may also be isolated by dissolving in MeOH and precipitating in ether the product remaining



after the distillation of HF. After filtration, the product is dried in the usual way and used direct in the next reaction step or purified by GPC.

5

#### Reaction\_type\_I

Conversion of 3- or 4-ANMP derivatives to luminol or isoluminol derivatives by hydrazinolysis.

10

2 mmol of peptide is dissolved in 15 ml of DMF and then 1.0  $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$  (hydrazine hydrate) is added and stirred at initially  $0^\circ\text{C}$  and then room temperature. The reaction solution is evaporated after 3 to 4 hours and the rest  
15 purified by GPC.

Instead of using the above method which is described here for the first time, the reaction can be effected in EtOH and accelerated by reflux boiling for about 30 minutes.

20 The product is isolated by evaporation and GPC.

#### Gel\_filtration\_chromatography

25 With GPC of protected peptide or amino acid derivatives, crude products of evaporated mother liquors obtained after crystallization, simplified processing and optimum yields are obtained. The substance is dissolved in MeOH and applied to a suitably sized column (volume 0.5 to  
30 7.5 l, length 100 cm) packed with Sephadex<sup>®</sup> LH-20 with MeOH and eluted with the same solvent. The eluate is fractionated into convenient volumes, and its UV absorption (254 nm) is continually determined. Fractions containing the product are checked for purity by TLC and  
35 the pure products are collected and evaporated.

To purify fully or partly deprotected amino acid and peptide derivatives an acetic acid solution of the crude product is moved to a suitably sized column (volume 0.5 to 2.0 l, length 60 cm) packed with Sephadex® G-15 swollen in 10 to 30% AcOH (aq) and eluated with the same solvent. Following the procedure described in the foregoing, the pure product-containing fractions are lyophilized, possibly after some evaporation at 20°C. For ion exchange and any required additional purification of a previously chromatographed product, a column with a slightly basic ion exchanger, Sephadex® QAE-25 in chloride form, swollen in MeOH:water 95:5 with the same medium as a solvent and eluant can be used. The pure product is lyophilized from water after evaporation.

15

25

TABLE

End- prod.	Inter- mediary prod.	Formula	Starting material	TLC		
				Synthesis	Yield	system R <sub>f</sub> (α)
I		H-D-Ile-Pro-Arg-Isl·2 HCl	le	C		A : 0.25 -98.3°
	1 e	Boc-D-Ile-Pro-Arg-Isl·HCl	ld	I	25	A : 0.57
	1 d	Boc-D-Ile-Pro-Arg-4-ANMP·HCl	lc	E		A : 0.59
	1 c	H-Pro-Arg-4-ANMP·2 HCl	lb	H	86	A : 0.14
	1 b	Cbo-Pro-Arg(NO <sub>2</sub> )-4-ANMP	la	B/E	85	P <sub>1</sub> : 0.32
	1 a	Cbo-Arg(NO <sub>2</sub> )-4-ANMP		A	72	P <sub>1</sub> : 0.37
II		Boc-Val-Pro-Arg-Isl·HCl	2a	D	32	A : 0.47 -101.9°
	2 a	H-Pro-Arg-Isl·2 AcOH	1c	I	60	M <sub>3</sub> : 0.18
III		Boc-Leu-Gly-Arg-Isl·HCl	3c	I	54	A : 0.47 -44.6°
	3 c	Boc-Leu-Gly-Arg-4-ANMP	3b	G	90	A : 0.47
	3 b	Boc-Leu-Gly-Arg(NO <sub>2</sub> )-4-ANMP	3a	B/D	53	P <sub>1</sub> : 0.12
	3 a	Cbo-Gly-Arg(NO <sub>2</sub> )-4-ANMP	1a	B/D	70	P <sub>1</sub> : 0.21
		Boc-Val-Leu-Gly-Arg-Isl·HCl	4b	I	28	A : 0.50 -50.5°
IV	4 b	Boc-Val Leu-Gly-Arg-4-ANMP·AcOH	4a	G	90	A : 0.47
	4 a	Boc-Val-Leu-Gly-Arg(NO <sub>2</sub> )-4-ANMP	3b	C/E	73	Pa : 0.37

BAD ORIGINAL



Inter- mediary End- prod.	Formula	Starting material	Synthesis Yield	TLC system $R_f$	( $\alpha$ )
V	H-D-Val-Leu-Arg-IsI·2 HCl	5d	C	A : 0.33	-62.4°
5 d	Boc-D-Val-Leu-Arg-IsI·HCl	5c	I	Pa <sub>6</sub> :0.29	
5 c	Boc-D-Val-Leu-Arg-4-ANMP	5b	G	Pa <sub>6</sub> :0.55	
5 b	Boc-D-Val-Leu-Arg(NO <sub>2</sub> )-4-ANMP	5a	B/E	P <sub>1</sub> :0.29	
5 a	Cbo-Leu-Arg(NO <sub>2</sub> )-4-ANMP	1a	B/D	P <sub>1</sub> :0.32	
VI	pGlu-Gly-Arg-IsI·HCl	6b	I	A : 0.20	-46.1°
6 b	pGlu-Gly-Arg-4-ANMP·AcOH	6a	G	A : 0.24	
6 a	Cbo-pGlu-Gly-Arg(NO <sub>2</sub> )-4-ANMP	3a	B/E	Pa : 0.08	
VII	Cbo-Gly-Pro-Arg-IsI·HCl	7a	I	A : 0.36	-49.9°
7 a	Cbo-Gly-Pro-Arg-4-ANMP·AcOH	1b	B/D	A : 0.37	
VIII	Boc-Ile-Glu(NC <sub>5</sub> H <sub>10</sub> )-Gly-Arg-IsI·HCl	8b	I	A : 0.45	-39.6°
8 b	Boc-Ile-Glu( $\gamma$ -pip)-Gly-Arg-4-ANMP	8a	E		
8 a	2 AcOH·H-Arg-4-ANMP	1a	H	M : 0.45	
IX	pNO <sub>2</sub> -Cbo-Phe-Pro-Arg-IsI·HCl	2a	B/D	A : 0.50	-74.2°
X	Cbo-Phe-Pro-Arg-IsI·HCl	2a	B/D	A : 0.53	-72.8°

Inter- mediary prod. prod.	Formula	Starting material				TLC	
		Starting material	Synthesis	Yield	system	R <sub>f</sub>	(α)
XI	Boc-Phe-Pro-Arg-Isl·HCl	2a	BD	55	A	:0.52	-76.5°
XII	H-Phe-Pro-Arg-Isl·2 HCl	XI	C	49	A	:0.26	-48.8°
XIII	Bz-Arg-Lum·HCl	13c	I	93	A	:0.49	+6.0°
	Bz-Arg-3-ANMP·AcOH	13b	H	75	A	:0.49	
	Bz-Arg(NO <sub>2</sub> )-3-ANMP	13a	B/F1	85	P <sub>1</sub>	:0.30	
	Cbo-Arg(NO <sub>2</sub> )-3-ANMP		A	31	A	:0.77	
XIV	pNO <sub>2</sub> -Bz-Arg-Isl·HCl	14b	I	61	A	:0.47	+21.2°
	pNO <sub>2</sub> -Bz-Arg-4-ANMP·AcOH	14a	H	42	A	:0.50	
	pNO <sub>2</sub> -Bz-Arg(NO <sub>2</sub> )-4-ANMP	1a	B/D	97	P <sub>1</sub>	:0.17	
XV	Bz-Arg-Isl·HCl	15b	I	79	A	:0.45	+4.1°
	Bz-Arg-4-ANMP·AcOH	15a	H	69	A	:0.47	
	Bz-Arg(NO <sub>2</sub> )-4-ANMP	1a	B/F1	82	P <sub>1</sub>	:0.22	
XVI	Cbo-Phe-Arg-Isl·AcOH	16a	I	36	Pa <sub>6</sub>	:0.22	-19.3°
	Cbo-Phe-Arg-4-ANMP·AcOH	8a	D	74	Pa <sub>6</sub>	:0.5	
XVII	Boc-Pro-Phe-Arg-Isl·HCl	17a	I	30	Pa <sub>6</sub>	:0.24	-58.4°
	Boc-Pro-Phe-Arg-4-ANMP·AcOH	8a	E	73	Pa <sub>6</sub>	:0.32	

Inter- mediary prod. prod.	Formula	Starting material				TLC	
		Starting material	Synthesis	Yield	system	R <sub>f</sub>	(α)
XVIII	H-Gly-Pro-Lys-Isl.2 HCl	18d	B	70	M <sub>3</sub>	0.25	-99.5°
	Boc-Gly-Pro-Lys(Cbo)-Isl	18c	I	50	Pa <sub>6</sub>	0.72	
	Boc-Gly-Pro-Lys(Cbo)-4-ANMP	18b	C/E	80	P <sub>1</sub>	0.58	
	Boc-Pro-Lys(Cbo)-4-ANMP	18a	C/E	84	P <sub>1</sub>	0.69	
XIX	Boc-Lys(Cbo)-4-ANMP		A		P <sub>1</sub>	0.63	
	H-Val-Leu-Lys-Isl.2 HCl	19c	B	59	M <sub>3</sub>	0.60	-42.9°
	Boc-Val-Leu-Lys(Cbo)-Isl	19b	I	80	Pa <sub>6</sub>	0.82	
	Boc-Val-Leu-Lys(Cbo)-4-ANMP	19a	C/E	78	P <sub>1</sub>	0.71	
XX	Boc-Leu-Lys(Cbo)-4-ANMP	18a	C/D	90	P <sub>1</sub>	0.62	
	Boc-Gly-Pro-Lys-Isl.HCl	20a	I	48	M <sub>3</sub>	0.81	-78.0°
	Boc-Gly-Pro-Lys-4-ANMP.ACOH	18c	G	96			
XXI	Boc-Val-Leu-Lys-Isl.HCl	21a	I	41	Pa <sub>6</sub>	0.38	-61.9°
	Boc-Val-Leu-Lys-4-ANMP.ACOH	19b	G				

BAD ORIGINAL



End- prod.	Inter- mediary prod.	Formula	Starting material	Synthesis	Yield	TLC system	R <sub>f</sub>	(α)
XXII		H-D-Leu-Ser-Arg-IsI·2 HCl	22e	C	70	A	:0.30	-40°
22 e		Boc-D-Leu-Ser-Arg-IsI·AcOH	22d	I	77	Pa <sub>6</sub>	:0.34	
22 d		Boc-D-Leu-Ser-Arg-4-ANMP·AcOH	22c	G	73			
22 c		Boc-D-Leu-Ser-(OBzl)-Arg(NO <sub>2</sub> )-4-ANMP	22b	E	87	P <sub>1</sub>	:0.41	
22 b		H-Ser-(OBzl)-Arg(NO <sub>2</sub> )-4-ANMP·HCl	22a	C	84	Pa <sub>6</sub>	:0.22	
22 a		Boc-Ser-(OBzl)-Arg(NO <sub>2</sub> )-4-ANMP	1a	B/E	80	P <sub>1</sub>	:0.43	
XXIII		Tos-Phe-Pro-Arg-IsI·HCl	XII	F2	41	A	:0.48	-68.3°
XXIV		H-D-Arg-Val-Tyr-IsI·2 HCl	24e	I	47	A	:0.32	-11.7°
24 e		H-D-Arg-Val-Tyr-4-ANMP·2 AcOH	24d	H	84	A	:0.33	
24 d		H-D-Arg(NO <sub>2</sub> )-Val-Tyr-4-ANMP·HCl	24c	B	80	A	:0.40	
24 c		α-Boc-D-Arg(NO <sub>2</sub> )-Val-Tyr(OBzl)-4-ANMP	24b	E	74	A	:0.88	
24 b		H-Tyr(OBzl)-4-ANMP·TFA	24a	C	93	Pa <sub>6</sub>	:0.60	
24 a		Boc-Tyr(OBzl)-4-ANMP		A		P <sub>1</sub>	:0.77	
XXV		Cbo-Gly-Gly-Arg-Lum·AcOH	25b	I	55	A	:0.37	-20.6°
25 b		Cbo-Gly-Gly-Arg-3-ANMP·AcOH	25a	D		A	:0.43	
25 a		H-Arg-3-ANMP·2 AcOH	13a	G		A	:0.26	

29

SUBSTITUTE SHEET



Inter- mediary prod. prod.	Formula	Starting material	Synthesis	Yield	TLC system R <sub>f</sub>	(α)
XXVI	Suc-Ala-Pro-Ala-IsI	26c	I	53	Pa <sub>6</sub> :0.33	-153.8°
26 c	Suc-Ala-Pro-Ala-4-ANMP	26b	B/FI	85	A :0.51	
26 b	Cbo-Ala-Pro-Ala-4-ANMP	26a	B/E	84	P <sub>1</sub> :0.60	
26 a	Cbo-Ala-4-ANMP		A	81	P <sub>1</sub> :0.57	
XXVII	Ac-Ala-Pro-Val-IsI	27c	I	47	Pa <sub>6</sub> :0.68	-164.2°
27 c	Ac-Ala-Pro-Val-4-ANMP	27b	B/FI	92	P <sub>1</sub> :0.29	
27 b	Cbo-Ala-Pro-Val-4-ANMP	27a	B/E	83	P <sub>1</sub> :0.63	
27 a	Cbo-Val-4-ANMP		A	68	P <sub>1</sub> :0.67	
XXVIII	Glt-Ala-Pro-Phe-IsI	28c	I	58	Pa <sub>6</sub> :0.61	-60.2°
28 c	Glt-Ala-Pro-Phe-4-ANMP	28b.	B/FI	82	Pa <sub>6</sub> :0.77	(i MeOH)
28 b	Cbo-Ala-Pro-Phe-4-ANMP	28a	B/E	83	P <sub>1</sub> :0.75	
28 a	Cbo-Phe-4-ANMP		A	86	P <sub>1</sub> :0.67	

SUBSTITUTE SHEET





### III. Determination of protease activity

#### Procedure

5 In a first step, the sample to be assayed for protease activity is allowed to react with the substrate. For this purpose, the buffer type, pH value, ionic strength and temperature should be decided on to warrant optimal reaction conditions for the enzyme in question. Thus the  
10 optimum activity for serine proteases within coagulation and fibrinolysis systems, as also trypsin, chymotrypsin, acrosine, elastase, urokinase, the streptokinase-plasminogen complex, plasminogen activators, Cl-esterase and its sub-components Clr and Cls as well as of the  
15 endotoxin-activated protease of the horseshoe crab lies within the pH range of 6.5 to 9.5. The ionic strength should be 0.05 to 0.40 and the temperature normally 25 to 37°C. All these proteases are determinable with substrates according to the invention.

20

The substrate concentration may be chosen in accordance with the degree of sensitivity required for the determination and depending on the preferred value in relation to the  $K_m$ -value. When extremely low protease  
25 activities are to be determined, that is, values approaching the lower limit of detection, blank values should be determined as in the case of pNA and MCA substrates. The usual substrate concentrations of the substrate-enzyme solution are  $10^{-3}$  to  $10^{-5}$  M. A stock  
30 solution of the substrate is prepared in water or buffer; with sparingly soluble substrates organic solvents are to be used, such as ethanol, dimethylsulphoxide, dimethylformamide or dimethylacetamide.

35 Depending on the degree of protease activity and substrate concentration, the reaction time usually is 0.5 to 5 minutes. With considerably longer reaction times, it is



important that the spontaneous hydrolysis of the substrate is very slow. The reaction is stopped by adding either acid or base to produce a change in pH great enough to discontinue further protease activity which usually happens at pH values lower than 5 or higher than 11.

The amount of released marker is then determined by a reaction as described in the foregoing. Any one of various reagents mentioned above may be used, and the volumes may vary.

The following examples describe test conditions under which linear relations were obtained between protease activity and appliance responses in the oxidation reactions.

A number of various oxidation systems have been used, as, for instance,

- |    |  |                   |
|----|--|-------------------|
| 20 | a) substrate-enzyme solution                                 |                   |
|    | (see examples below)   | 10 - 50 $\mu$ l   |
|    | b) 0.05 M NaOH in water                                      | 250 - 750 $\mu$ l |
|    | d) 5 to 10 $\mu$ M hematin in 0.1 M $\text{Na}_2\text{CO}_3$ |                   |
|    | in water   | 20 - 100 $\mu$ l  |
| 25 | c) 0.1 to 0.5 M $\text{H}_2\text{O}_2$ in water              | 20 - 100 $\mu$ l  |

The pH-regulating solution (b) is adapted to the applied catalyst/oxidation promoting compound (c). The following modifications were used:

- 30
- (b) phosphate buffer pH 11.6 and (c) hematin as above
  - (b) NaOH as above and (c) catalase 30,000 unit per ml of water
  - (b) 0.08 M  $\text{Na}_2\text{CO}_3$  pH 11.2 and (c) Microperoxidase
- 35
- (Sigma, U.S.A. Prod.No. M 6756, 0.4 mg/ml 10 mM tris buffer and HCl, pH 7.4, diluted 50 times with 50 mM borate buffer, pH 8.4)

- (b) 50 mM borate buffer pH 8.4 and (c) Microperoxidase.

Instead of using the basic environment of the oxidation system to stop protease activity, 0.1 to 1.0 parts by volume of 20 to 100% acetic acid can be added to the enzyme-substrate solution. The content of acetic acid does not interfere with the pH of the oxidation solution.

Thus, determinations can be made with minute volumes (10 - 50  $\mu$ l) of substrate-enzyme solution. The optimum volume (300 to 1,000  $\mu$ l) of oxidation solution allowable for the used appliance is chosen.

#### Test 1

15

a) 50  $\mu$ l  $10^{-4}$  Boc-Val-Leu-Lys-Isl  $\cdot$  HCl (XXI) in a tris buffer pH 8.3, I = 0.3 after being kept at 25°C for varying lengths of time for observation of spontaneous hydrolysis of substrate in typical protease determination environment.

20

- b) 700  $\mu$ l 50 mM NaOH
- c) 20  $\mu$ l 10 mM hemine
- d) 100  $\mu$ l 80 mM  $H_2O_2$

25 Result: Spontaneous hydrolysis 0.03% per hour, that is, after one hour,  $3 \cdot 10^{-9}$  M isoluminol had been liberated, thus, the substrate is very stable.

#### Test 2

30

a) is 50  $\mu$ l of either of the following:

- $10^{-4}$  M Boc-Val-Leu-Lys-Isl  $\cdot$  HCl (XXI)
- substrate according to the above plus  $10^{-5}$  -  $10^{-10}$  M isoluminol
- 35 -  $10^{-5}$  M Boc-Val-Leu-Lys-Isl  $\cdot$  HCl (XXI)
- substrate according to the above plus  $10^{-5}$  -  $10^{-10}$  M isoluminol

b) - d) as in Test 1.

Result: The appliance response is in rectilinear proportion to the amount of isoluminol; in the lowest concentration range -  $10^{-7}$  -  $10^{-9}$  and  $10^{-8}$  -  $10^{-9}$ , respectively - the best results are obtained after the usual corrections for background contributions of the substrate.  $1 \cdot 10^{-9}$  M can be exactly determined. Isoluminol causes an appliance response 2,500 times larger than that of the substrate at the corresponding concentration, that is, the background is 0.04%.

Tests 3 to 7 are examples of protease activity determinations.

15

Test 3

Urokinas and pGlu-Gly-Arg-Isl · HCl (VI)

20 Substrate-enzyme solution:

Tris buffer pH 9.0 I = 0.05	800 µl
Urokinase (AB Leo, Sweden) 2.5 - 20	
Plough units per	100 µl
25 Substrate $10^{-3}$ M in water	200 µl
Reaction time 5 minutes,	
temperature $37^{\circ}\text{C}$	
20% AcOH	100 µl

30 50 µl of the solution is used for determination of the amount of isoluminol according to Test 1.

35

Test 4

Thrombin and Tos-Phe-Pro-Arg-Iso · HCl (XXIII)

## 5 Substrate-enzyme solution:

- Tris buffer pH 8.3 I = 0.15 800  $\mu$ l  
Thrombin (Ortho, U.S.A.) 0.02-0.32 NIH-  
units per 100  $\mu$ l  
10 Substrate  $10^{-3}$  M in water 100  $\mu$ l  
Reaction time 1 minute,  
temperature 37°C  
20% AcOH 100  $\mu$ l
- 15 50  $\mu$ l of the solution is used for determination of the  
amount of isoluminol according to Test 1.

Test 5

20

Factor Xa and Boc-Ile-Glu(NC<sub>5</sub>H<sub>10</sub>)-Gly-Arg-pNA · HCl  
(VIII)

## Substrate-enzyme solution:

25

- Tris buffer pH 8.3 I = 0.25 800  $\mu$ l  
Factor Xa (Diagnostic Reagents, England)  
0.05 - 0.8 units (U) per 100  $\mu$ l  
Substrate  $10^{-3}$  in water 200  $\mu$ l  
30 Reaction time 1 minute,  
temperature 37°C  
20% AcOH 100  $\mu$ l
- 50  $\mu$ l of the solution is used for determination of  
35 isoluminol according to Test 1.

BAD ORIGINAL



Test 6

Plasmin and Boc-Val-Leu-Lys-Iso · HCl (XXI)

## 5 Substrate-enzyme solution:

Tris buffer pH 7.4, I = 0.15	700 $\mu$ l
Plasmin (Kabi, Sweden)	
0.00125-0.02 U per	100 $\mu$ l
10 Substrate $10^{-3}$ in water	300 $\mu$ l
Reaction time 1 minute, temperature 37°C	
20% AcOH	100 $\mu$ l

15. 50  $\mu$ l of the solution is used for determination of  
isoluminol according to Test 1.

Test 7

20

Trypsin and substrates No. V, VI, VIII, X, XI, XII,  
XIII, XV, XVI and XX

## Substrate-enzyme solution:

25

$1 \cdot 10^{-5}$ - $1 \cdot 10^{-9}$ M trypsin in 1 mM HCl	30 $\mu$ l
Substrate 1 - $1.5 \cdot 10^{-3}$ M in water	50 $\mu$ l
Tris buffer 10 mM pH 8.3	210 $\mu$ l
Reaction time 5 minutes at 30 room temperature.	

25  $\mu$ l of the substrate enzyme solution is used for  
determination of the amount of marker of the system

35 0.8 mM $\text{Na}_2\text{CO}_3$ pH 11.2	240 $\mu$ l
Microperoxidase	20 $\mu$ l
90 mM $\text{H}_2\text{O}_2$ in water	20 $\mu$ l

The results from Tests 3 to 7 show a rectilinear relation between appliance response and protease volume. The amount of released marker per time unit is of the magnitude expected on the basis of known data on corresponding substrate structures with chromogenic and fluorogenic markers.

Claims

1. Peptide derivatives characterized by the fact that they are acyl derivatives of luminol (5-amino-2,3-dihydro-1,4-phthalazinedione) or isoluminol (6-amino-2,3-dihydro-1,4-phthalazinedione) where the acyl residue is an amino acid, or amino acid sequence, with 2 to 4 amino acid residues, coupled with an amide bond, and where the  $\alpha$ -amino group is either free or acylated.
2. Compounds according to claim 1, where the C-terminal amino acid is L-arginine, L-lysine, L-alanine, L-phenylalanine, L-tyrosine, L-valine or L-proline.
3. Compounds according to claim 1, where the amino acids may be chosen from straight or branched aliphatic amino acids with 2 - 6 carbon atoms which may also be hydroxi-substituted, aromatic amino acids with 8 or 9 carbon atoms which may also be hydroxi-substituted or cyclic imino acids with 4 - 6 carbon atoms, or arginine, lysine, pyroglutaminic acid, glutaminic acid or aspartic acid, where the latter two may be free acids or ester- or amido-derivatives of the  $\gamma$ - or  $\beta$ -carboxy group, respectively.
4. Compounds according to claim 1, where - in case the compound is a peptide derivative - the N-terminal amino acid appears in the D-form with the  $\alpha$ -amino group being either free or a protonized acid addition salt.
5. Compounds according to claim 2, where the 1 - 3 N-terminal amino acids of the peptide derivative may be chosen from Gly, Ala, Val, Leu, Ile, Pro, Pip, Phe, Tyr, Arg, Lys, Ser, Thr, pGlu, Glu or Asp, or esters with 1 - 4 carbon atoms of Glu or Asp, Asn or Gln or substituted amides with substituents containing 1 - 5 carbon atoms of Asn or Gln.



6. Compounds according to claim 1 where the N-terminal  $\alpha$ -amino group of the amino acid or peptide derivative is acylated with Bz, Cbo,  $\text{pNO}_2\text{-Bz}$ ,  $\text{pNO}_2\text{-Cbo}$ , Boc, Ac, trifluoroacetyl, Glt, Sac or Tos.

5

7. Peptide derivatives characterized by the general formula



10

where

$\text{R}_1$  = H or acyl such as Bz,  $\text{pNO}_2\text{Bz}$ , Boc, Cbo,  $\text{pNA}_2\text{Cbo}$ , Ac, Suc, Glt or Tos

15  $\text{A}_4$  = Val, Ile, Ala, Gly or nil

$\text{A}_3$  = Pro, Phe, Gly, Val, pGlu, Leu, Glu(pip), Ala, Glu, Glu(OMe), Arg, Ile Tyr or nil

$\text{A}_2$  = Phe, Pro, Leu, Ser, Gly, Val, Ala or nil

$\text{A}_1$  = Arg, Lys, Tyr, Phe, Ala, Val, Pro

20  $\text{R}_2$  = luminol (5-amino-2,3-dihydro-1,4-phthalazinedione), isoluminol (6-amino-2,3-dihydro-1,4-phthalazinedione)

and where the N-terminal amino acid of the peptide sequence appears in L- or D-form.


25 8. Method in laboratory diagnostics of proteases, characterized by the fact that a compound according to any of claims 1-7 is used as a substrate.

9. Method for the preparation of peptide derivates  
30 according to any one of claims 1-7 characterized by the fact that the syntheses are carried out by gradual binding of  $\text{R}_2$  to  $\text{A}_1$  which, when required, is followed by continued gradual composition via  $\text{A}_2$ ,  $\text{A}_3$ ,  $\text{A}_4$ ,  $\text{R}_1$  according to procedures known per se.

35

# INTERNATIONAL SEARCH REPORT

International Application No PCT/SE81/00235

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>1</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC <b>3</b>		
<b>C 07 C 103/52, C 07 D 237/32, C 12 Q 1/38</b>		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>4</sup>		
Classification System	Classification Symbols	
IPC 3	C 07 C 103/52, C 07 D 237/26,30,32, C 12 Q 1/34-38,56,66, G 01 N 31/14, 33/16 <div style="text-align: right;">.../...</div>	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>5</sup>		
SE, NO, DK, FI classes as above		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>		
Category <sup>6</sup>	Citation of Document, <sup>15</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
A	SE, B, 407 058 (AB KABI) 12 March 1979 (12.03.79)	1-9
A	DE, A1, 2 824 917 (CORNING GLASS WORKS) 1 February 1979 (01.02.79)	1-8
X A	US, A, 4 181 650 (CHARLES L MAIER JR) 1 January 1980 (01.01.80)	1 2-8
X	Proc. Natl. Acad. Sci. U.S.A. 1975, 72 (1), p 338-342	1
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>*</sup> Special categories of cited documents: <sup>19</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search <sup>2</sup>	Date of Mailing of this International Search Report <sup>2</sup>	
1981-12-07	1981-12-10	
International Searching Authority <sup>1</sup>	Signature of Authorized Officer <sup>20</sup>	
Swedish Patent Office	 Elisabeth Carlberg	

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

II

Fields Searched (cont)

US C1 195:99, 103.5, 127;  
260:112.5, 250;  
435:4, 18, 19, 23, 24;  
544:224, 233, 235, 237

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>10</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers ..... because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:

2. ☐ Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>11</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.